drugset / Trial / NCT05159245
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Timeline
- Start
- 2021-12-10
- Primary completion
- 2026-11-25
- Completion
- 2026-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | — |
| Subject | Alectinib | Small molecule | — | — |
| Subject | Apalutamide | Small molecule | — | — |
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Cobimetinib | Small molecule | — | — |
| Subject | Dabrafenib | Small molecule | — | — |
| Subject | Entrectinib | Small molecule | — | — |
| Subject | Pemigatinib | Small molecule | — | — |
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Subject | Regorafenib | Small molecule | — | — |
| Subject | Tepotinib | Small molecule | — | — |
| Subject | Trametinib | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Subject | Vemurafenib | Small molecule | — | — |
| Subject | Vismodegib | Small molecule | — | — |